Medical Marijuana Investors: The Floodgates Are Opening – Nasdaq
What’s behind the booming profit potential of legal marijuana? Let me start by paraphrasing something I heard a physician say in a televised interview during the early days of some US states allowing medicinal use.
When asked if marijuana could have medicinal value, he responded, “For patients who have terminal conditions like cancer or AIDS, if marijuana eases their suffering, it would basically be barbaric to deny it to them.”
“Do I believe that some of the compounds present in marijuana plants could someday be the basis of clinically tested, FDA-approved pharmaceutical products in the future? Absolutely. Most drug compounds are derivations of plant compounds and there’s no reason to believe that the marijuana plant might not also be valuable in that respect.”
“Would I advise a patient to light a plant on fire and inhale the combustants in unknown dosage in an attempt to cure an illness? Absolutely not, because that’s simply not the way that the medical community administers any medicine. We demand much more precision than that.”
Those words were prescient, because although some of the early “medicinal” use was a thinly veiled attempt to make recreational use less illegal, marijuana has become the basis for drug compounds that promise to improve the health outcomes of patients and produce profits for the companies who produce them.
THC vs CBD
There is a crucial distinction to be made between Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the two primary active compounds in marijuana. (There are as many as 100 more cannabinoid compounds also sometimes present in the plant, based on the strain.)
THC is psychoactive and makes users feel high. CBD is not psychoactive and has no significant effect on mood or perception.
While some medical users also seek benefits from THC, it’s CBD that has shown the most promise in the development of drugs.
There are whole families who have moved to states where Marijuana is legal in order to procure medicines that help their children. Specifically in the case of children who have certain forms of epilepsy that cause dozens of painful seizures daily, some strains of marijuana offer nearly immediate relief. These people quit their jobs, sold the house, pulled up the stakes and moved to Colorado to get drugs made from Cannabidiol – also known as “CBD”, a non-intoxicating compound in marijuana – because they have been able to reduce or eliminate the seizures, even when other medicines and surgery could not.
Surely you can imagine that political beliefs about marijuana legalization get thrown right out of the window when someone is forced to helplessly watch their child or grandchild endure a painful seizure and relief is potentially within reach.
Continued . . .
Pot Stocks to Buy ASAP
Pent-up demand released by wave after wave of marijuana legalization has created a new industry that is surging from $14.9 billion to an expected $42.7 billion in 2024.
With 10 to 16 more U.S. states and all of Mexico pushing for legalization in 2020, growth could skyrocket even higher.
Zacks launched a unique approach to this space and quickly closed access to limit the number of investors who share its picks. Entry has briefly re-opened but only until midnight Sunday, March 8.
See live buys now >>
This is exactly the type of apolitical momentum that might make legitimate medical marijuana medicines more accessible, even independent of the laws about recreational use. In fact, the most recent US Farm Bill, signed in December 2018, fully legalized the production of hemp – a variant of the cannabis plant that has significant industrial and textile uses and contains extremely small amounts of the THC but can be harvested for CDB to make non-psychoactive drugs for both the pharmaceutical industry and the over-the-counter health and wellness industry. (More on this later…)
The Drug Schedule
Under the Controlled Substances Act, all substances with the potential for addiction or abuse are placed into one of five “schedules” according to a combination of its potential legitimate uses and relative danger. Schedule 1 drugs have been deemed to have a high potential for abuse or dependency and no recognized medical applications. Marijuana is included in Schedule 1, along with LSD and heroin. In comparison, cocaine and opioids are Schedule 2 substances – not necessarily because anyone thinks they’re less dangerous than marijuana, but because they do have recognized medical value.
Alcohol and tobacco were both intentionally left off of the controlled substances schedule – despite their potential for abuse/harm and lack of medical value – presumably because of the political influence of established industries.
It’s widely believed (and supported by recordings of oval office conversations that became part of the Watergate scandal) that president Nixon lobbied for making marijuana a Schedule 1 drug with the explicit intention of harming groups that were not supportive of his politics and policies. In 1970 when the Controlled Substances Act was signed into law, anti-war protestors and minority groups were among the most common users of marijuana and Nixon took the opportunity to make their drug of choice as illegal as possible.
Recently, one of the biggest ongoing criticisms of marijuana prohibition is that minorities have been incarcerated for possession or use at a disproportionate rate based on demographics and use patterns. In a sense, the Nixon policy has remained stubbornly ingrained in present day law-enforcement.
CBD, the Farm Bill, the FDA and 7-11
The most recent Farm Bill, signed in late 2018, broadly legalized the production and sale of hemp, which is defined as containing less than 0.3% THC but can be rich in CBD. It also de-schedules CBD, paving the way for large-scale research and development.
This is great news for companies hoping to develop, test and sell CBD-based pharmaceuticals in the US, but it also creates a confusing situation in which products can now be sold virtually anywhere that contain CBD, promising all sorts of health and wellness benefits.
This is an important distinction. The investment opportunities are likely to be in true pharmaceutical research in which companies perform rigorous testing in controlled trials and report the results to the FDA for approval as a prescription drug, not in outfits that sell CBD products of uncertain strength and purity over the counter at convenience stores and make dubious claims about weight-loss, wrinkle reduction, etc.
It’s not impossible that some of these purveyors will be able to turn a profit – gullibility is a powerful force and snake oil salesmen do profit sometimes – but it’s not where we are going to focus our investment research efforts.
The US FDA has been actively issuing warning letters to companies selling CBD in ways that violate the Federal Food, Drug and Cosmetic Act (FD&C Act) and also recently published a revised Consumer Update detailing safety concerns about CBD more broadly.
The agency specifically took aim at the idea that CBD “can’t hurt,” and that it is therefore appropriate to add it indiscriminately to food, beverage and topical products. They also point out that there may be significant questions about the safety of the products currently available, some of which have been found to be contaminated with pesticides and heavy metals. While progress toward full legalization of marijuana in the US will have significant impact on companies who grow and sell it for recreational purposes, the floodgates are already open for the development of legitimate marijuana-based medicine.
Currently, one US listed company had an FDA approved drug with CBD as the main active ingredient – GW Pharmaceuticals (GWPH). GW’s Epilepsy drug Epidiolex received the lowest possible Schedule 5 classification from the DEA and GW has several other cannabinoid-based drugs in the R&D pipeline, including compounds for Multiple Sclerosis and Autism.
Incidentally, though insurers will probably pay less, the retail price for a year of treatment with Epidiolex is $32.5K, so there’s also big money in CBD treatments with proven results. In the most recent quarterly report, GW announced that more than 12,000 patients had been prescribed Epidiolex by more than 2,500 physicians. Net sales through Q2 were over $108 million.
The company continues to report that 93% of Americans are now covered by health plans that will pay for Epidiolex. GW’s phase 3 trials for use in another seizure disorder – Tubular Sclerosis Complex – have been promising and fast-track “Investigational New Drug” (IND) phase 3 trials as a treatment for Rett’s syndrome began in Q2.
GW also received approval for Epidyolex (same drug, slightly different name) in the European Union and a favorable ruling from the United Kingdom’s National Institute of Health and Care Excellence regarding the cost and efficacy of the drug, paving the way for routine reimbursement from the National Health Service.
Even more research from GW and many other companies is underway and health scientists are optimistic that cannabis will provide the basis of medicines for all sorts of diseases. The US Drug Enforcement Agency (DEA) announced in August 2019 that they would be streamlining the application process for the approval of growers who want to provide cannabis for research purposes.
One of the most exciting pharmaceutical applications of cannabis is the development of replacements for deadly opioids in relieving pain. The Centers for Disease Control (CDC) estimates that 470,000 Americans died between 1999 and 2018 from opioid overdoses. The State of Oklahoma was recently awarded a $572 million judgement as plaintiff in a lawsuit against Johnson and Johnson (JNJ) because of its role in manufacturing components for the drugs that are blamed for taking the lives of 6,000 Oklahoma citizens and uprooting the lives of many more who require extensive social services at the expense of the state.
Pharmaceutical manufacturers face thousands of lawsuits from individuals and municipalities because of their role in producing and distributing addictive and deadly opioids. The cost of judgements and settlements could eventually stretch into hundreds of billions of dollars.
New research is finding that CBD formulations can be as effective at relieving pain symptoms as opioid drugs, but with considerably less risk. Because it does not produce a perceptible psychoactive effect, CBD has a low potential for abuse. More importantly, even at high doses, it causes no acute health issues – no fatal overdoses have ever been reported.
Though some consumers may use the current crop of recreational and medicinal cannabis products for pain, the real growth is likely to happen in pharmaceutical products that have been clinically tested for safety and efficacy and sold by prescription.
There are several big companies who are increasingly feeling a need to replace opioid drugs – from a lost revenue perspective as well as to improve public opinion. It’s easy to see how a small pharma company with a cannabis-based replacement that has been approved by the FDA (or looks likely to be approved soon) would be very attractive as an acquisition target.
The success of drugs like Epidiolex is just the tip of the iceberg. Research into all the ways that compounds from the cannabis plant can be turned into effective and safe pharmaceuticals is really just beginning. Lab work and clinical trials with patients take time, but investors should expect a large number of new pharmacological compounds to be introduced in the coming months and years.
Catching Blockbuster Opportunities Early
At Zacks we’re monitoring political developments very closely as well as tracking individual stocks.
The marijuana industry looks to almost TRIPLE from $14.9 billion in 2019 to $42.7 billion by 2024. Yet only a few growers, pharmaceuticals, financial firms, suppliers – both established and start-ups – are the true innovators and offer exceptional profit potential.
So if you don’t want to devote the constant attention and painstaking analysis to find these often little-known tickers early in their profit cycles, we can find them for you.
You’re invited to take part in the portfolio service I’m directing, Zacks Marijuana Innovators.
Our approach is aggressive but responsible and vigilant. We pursue double and triple-digit gains, alerting you to what and when to buy and sell. I’ll also brief you on breaking market news that directly affects your investments.
New Stock Monday Morning
I plan to post a big-upside trade at 11:05 am ET Monday, and you can be among the first to see it. Selling for under $10 per share, it’s a small-cap grower with potential to soar in the months ahead.
Important Note: This portfolio has been closed to public entry since December to limit the number of investors jumping on the stocks. Now it has re-opened, but only briefly.
It closes again midnight Sunday, March 8.
Don’t miss the chance to see our stocks and be first in line for the newest trade.
Look Inside Marijuana Innovators Right Now >>
Zacks Stock Strategist
David Borun is Zacks’ Cannabis Stock Strategist. He applies 20 years of trading experience and several months of concentrated industry study to the direction of our unique portfolio service, Zacks Marijuana Innovators.
Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This article originally appeared here in https://www.nasdaq.com/articles/medical-marijuana-investors:-the-floodgates-are-opening-2020-03-06